Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.39M Sell
3,851
-3,259
-46% -$1.12M 0.24% 93
2026
Q1
$2.5M Buy
7,110
+2,020
+40% +$720K 0.62% 28
2025
Q4
$1.67M Sell
5,090
-1,753
-26% -$556K 0.36% 52
2025
Q3
$1.93M Buy
+6,843
New +$1.98M 0.37% 50
2025
Q2
Sell
-5,072
Closed -$1.58M 512
2025
Q1
$1.58M Buy
5,072
+3,496
+222% +$1.03M 0.31% 69
2024
Q4
$411K Buy
+1,576
New +$468K 0.09% 250

Other funds holding AMGN

111 Capital's AMGN Position: Q2 2026 in Review

111 Capital reduced its Amgen (AMGN) stake by 46% in Q2 2026, selling an estimated $1.12M and leaving 3,851 shares worth $1.39M. The position accounts for 0.24% of the portfolio, ranked #93.

111 Capital first reported a position in AMGN in Q4 2024 and has held it in 6 quarters since. The position peaked at $2.5M in Q1 2026. 3,160 funds tracked by Wall St. Rank hold AMGN as of Q2 2026.

  • 111 Capital held 3,851 shares of Amgen worth $1.39M as of Q2 2026.
  • 111 Capital sold 3,259 Amgen shares in Q2 2026, an estimated $1.12M.
  • Amgen made up 0.24% of 111 Capital's portfolio in Q2 2026, its #93 holding.
  • 111 Capital first reported a position in Amgen in Q4 2024 and has held it in 6 quarters since.
  • 111 Capital's Amgen position peaked at $2.5M in Q1 2026.
  • 3,160 funds tracked by Wall St. Rank held Amgen as of Q2 2026.

Based on 111 Capital's 13F filing for Q2 2026, filed 5 Aug 2026.